Cargando…

Optimizing Molecular Minimal Residual Disease Analysis in Adult Acute Lymphoblastic Leukemia

SIMPLE SUMMARY: Minimal/measurable residual disease (MRD) monitoring is a powerful and independent predictor of outcomes in both children and adult acute lymphoblastic leukemia (ALL). MRD monitoring enables patients’ stratification into different risk-adapted treatment arms; it guides treatment deci...

Descripción completa

Detalles Bibliográficos
Autores principales:	Della Starza, Irene, De Novi, Lucia Anna, Elia, Loredana, Bellomarino, Vittorio, Beldinanzi, Marco, Soscia, Roberta, Cardinali, Deborah, Chiaretti, Sabina, Guarini, Anna, Foà, Robin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856386/ https://www.ncbi.nlm.nih.gov/pubmed/36672325 http://dx.doi.org/10.3390/cancers15020374

Ejemplares similares

Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical Advances
por: Della Starza, Irene, et al.
Publicado: (2019)

PB1711: DROPLET DIGITAL PCR DETECTION OF THE T315I BCR::ABL1 KD MUTATION IN ADULT PH-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
por: Cardinali, Deborah, et al.
Publicado: (2023)

Applicability of droplet digital polymerase chain reaction for minimal residual disease monitoring in Philadelphia‐positive acute lymphoblastic leukaemia
por: Ansuinelli, Michela, et al.
Publicado: (2021)

Research Topic: Measurable Residual Disease in Hematologic Malignancies. Can digital droplet PCR improve measurable residual disease monitoring in chronic lymphoid malignancies?
por: Assanto, Giovanni Manfredi, et al.
Publicado: (2023)

P1232: NON-INVASIVE MINIMAL RESIDUAL DISEASE ANALYSIS BY IMMUNOGLOBULIN GENE REARRANGEMENTS ON CIRCULATING TUMOR DNA PREDICTS THE OUTCOME OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA
por: Soscia, Roberta, et al.
Publicado: (2023)

Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913
por: Chiaretti, Sabina, et al.
Publicado: (2020)

Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?
por: Del Giudice, Ilaria, et al.
Publicado: (2019)

Droplet Digital PCR Improves IG-/TR-based MRD Risk Definition in Childhood B-cell Precursor Acute Lymphoblastic Leukemia
por: Della Starza, Irene, et al.
Publicado: (2021)

Myeloid/T-cell acute lymphoblastic leukemia in children and adults
por: Chiaretti, Sabina, et al.
Publicado: (2011)

Prognostic implications of additional genomic lesions in adult Philadelphia chromosome-positive acute lymphoblastic leukemia
por: Fedullo, Anna Lucia, et al.
Publicado: (2019)

Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial
por: Bassan, Renato, et al.
Publicado: (2023)

Diagnosis and Subclassification of Acute Lymphoblastic Leukemia
por: Chiaretti, Sabina, et al.
Publicado: (2014)

Case report: Ponatinib as a bridge to CAR-T cells and subsequent maintenance in a patient with relapsed/refractory Philadelphia-like acute lymphoblastic leukemia
por: Giglio, Fabio, et al.
Publicado: (2023)

Long-Term Host Immune Modulation Following Tisagenlecleucel Administration in Patients with Diffuse Large B-Cell Lymphoma and B-Lineage Acute Lymphoblastic Leukemia
por: Guarini, Anna, et al.
Publicado: (2023)

Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia
por: Kruse, Aaron, et al.
Publicado: (2020)

Sialylation regulates migration in chronic lymphocytic leukemia
por: Natoni, Alessandro, et al.
Publicado: (2023)

Prognostic and therapeutic role of targetable lesions in B-lineage acute lymphoblastic leukemia without recurrent fusion genes
por: Messina, Monica, et al.
Publicado: (2016)

Genomic Characterization of Acute Leukemias
por: Chiaretti, Sabina, et al.
Publicado: (2014)

Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study
por: Cerrano, Marco, et al.
Publicado: (2022)

National Italian Delphi panel consensus: which measures are indicated to minimize pegylated-asparaginase associated toxicity during treatment of adult acute lymphoblastic leukemia?
por: Lussana, Federico, et al.
Publicado: (2020)

High rate of minimal residual disease responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2)
por: Mauro, Francesca R., et al.
Publicado: (2020)

Real-World Multicenter Experience in Tumor Debulking Prior to Blinatumomab Administration in Adult Patients With Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
por: Bonifacio, Massimiliano, et al.
Publicado: (2022)

Practical guidance for the management of acute lymphoblastic leukemia in the adolescent and young adult population
por: Carobolante, Francesca, et al.
Publicado: (2020)

Minimal Residual Disease in Adult Acute Lymphoblastic Leukemia: Egyptian Experience
por: Ibrahim, Rasha Ibrahim, et al.
Publicado: (2022)

Acute lymphoblastic leukemia: age and biology
por: Foà, Robin
Publicado: (2011)

Venetoclax and Bortezomib in Relapsed/Refractory Early T-Cell Precursor Acute Lymphoblastic Leukemia
por: La Starza, Roberta, et al.
Publicado: (2019)

Current Strategies for the Detection of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia
por: Rocha, Juliana Maria Camargos, et al.
Publicado: (2016)

Sources of error in measurement of minimal residual disease in childhood acute lymphoblastic leukemia
por: Latham, Sue, et al.
Publicado: (2017)

Minimal Residual Disease in Acute Lymphoblastic Leukemia: Current Practice and Future Directions
por: Contreras Yametti, Gloria Paz, et al.
Publicado: (2021)

T-Cell Acute Lymphoblastic Leukemia: Biomarkers and Their Clinical Usefulness
por: Bardelli, Valentina, et al.
Publicado: (2021)

The utility of multiparametric flow cytometry for the detection of minimal residual disease in acute lymphoblastic leukemia
por: Cunha, Fernanda Gonçalves Pereira, et al.
Publicado: (2012)

Minimal residual disease in acute lymphoblastic leukemia: technical aspects and implications for clinical interpretation
por: Kim, In-Suk
Publicado: (2020)

Circulating microRNAs as minimal residual disease biomarkers in childhood acute lymphoblastic leukemia
por: Rzepiel, Andrea, et al.
Publicado: (2019)

Real-world use of blinatumomab in adult patients with B-cell acute lymphoblastic leukemia in clinical practice: results from the NEUF study
por: Boissel, Nicolas, et al.
Publicado: (2023)

Clinical significance of occult central nervous system disease in adult acute lymphoblastic leukemia: a multicenter report from the Campus ALL Network
por: Del Principe, Maria Ilaria, et al.
Publicado: (2019)

Blinatumomab vs historic standard‐of‐care treatment for minimal residual disease in adults with B‐cell precursor acute lymphoblastic leukaemia
por: Gökbuget, Nicola, et al.
Publicado: (2020)

Prognostic Significance and Treatment Implications of Minimal Residual Disease Studies in Philadelphia-Negative Adult Acute Lymphoblastic Leukemia
por: Spinelli, Orietta, et al.
Publicado: (2014)

P361: HIGH REMISSION AND SURVIVAL RATE IN ADULTS WITH MINIMAL RESIDUAL DISEASE-POSITIVE OR RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA TREATED WITH BLINATUMOMAB IN ROUTINE CLINICAL PRACTICE
por: Chiaretti, Sabina, et al.
Publicado: (2023)

A multicenter total therapy strategy for de novo adult Philadelphia chromosome positive acute lymphoblastic leukemia patients: final results of the GIMEMA LAL1509 protocol
por: Chiaretti, Sabina, et al.
Publicado: (2021)

Transcriptome Analysis of Minimal Residual Disease in Subtypes of Pediatric B Cell Acute Lymphoblastic Leukemia
por: Sitthi-amorn, Jitsuda, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ksabe7lip5uaf1ics06iqa1ghf